MedTrace Logo

The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)

NCT04329923 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 173

Last updated 2020-12-10

Study results available
· View outcomes & findings →

Summary

The PATCH trial (Prevention And Treatment of COVID-19 with Hydroxychloroquine) is funded investigator-initiated trial that includes 3 cohorts. Cohort 1: a double-blind placebo controlled trial of high dose HCQ as a treatment for home bound COVID-19 positive patients; Cohort 2: a randomized study testing different doses of HCQ in hospitalized patients; Cohort 3: a double blind placebo controlled trial of low dose HCQ as a preventative medicine in health care workers.

Conditions

Interventions

DRUG

Hydroxychloroquine Sulfate 400 mg twice a day

Antimalarial compound

DRUG

Hydroxychloroquine Sulfate 600 mg twice a day

Antimalarial compound

DRUG

Hydroxychloroquine Sulfate 600 mg once a day

Antimalarial compound

DRUG

Placebo oral tablet

Placebo

Sponsors & Collaborators

  • Ravi Amaravadi, MD

    lead OTHER

Principal Investigators

  • Ravi Amaravadi, MD · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-09
Primary Completion
2020-11-11
Completion
2020-11-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04329923 on ClinicalTrials.gov